// App-Quantinova.ai

: Changes in biomarkers in patients with idiopathic pulmonary fibrosis (IPF) treated with nintedanib and sildenafil

Researchers

Presenter

  • Eric White

Principal Investigators

  • Bruno Crestani

  • Andreas Gnther

  • Toby M Maher

  • Carina Ittrich

  • Claudia Diefenbach

  • Klaus B Rohr

  • Manuel Quaresma

  • Martin Kolb

Medical Centers

  • University of Michigan, Division of Pulmonary & Critical Care Medicine, Ann Arbor, MI, United States,

  • Hôpital Bichat, Pneumologie, Paris, France

  • Center for Interstitial and Rare Lung Diseases, Justus-Liebig University Gießen; member of the German Center for Lung Research, Gießen, Germany

  • National Heart and Lung Institute, Imperial College London, UK and National Institute for Health Research Clinical Research Facility, Royal Brompton Hospital, London, UK, London, United Kingdom

  • Boehringer Ingelheim Pharma GmbH and Co. KG, Biberach, Germany

  • Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany,

  • McMaster University and St. Joseph’s Healthcare, Hamilton, Ontario, Canada

Locations

  • United States

  • France

  • Germany

  • United Kingdom

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Pulmonary/Respiratory Diseases

Disease

  • Idiopathic pulmonary fibrosis

Biomarkers

  • N/A

Drug/Treatment

  • Nintedanib

  • Sildenafil citrate

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved